Skip to main content

Biogen Q3 FY2026 results

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

Biogen reported revenue of $2.80 billion, up 10.6% from a year earlier, net income of −$20.6 million and diluted earnings per share of −$0.14 against $3.17 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 28 Oct 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

Biogen Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$2.80B$2.53B+10.6%
Gross profit$2.06B$1.86B+10.5%
Gross margin73.3%73.4%−0.1 pts
Operating income−$9.00M$557.3M—
Operating margin−0.3%22.0%−22.3 pts
Net income−$20.60M$466.5M—
Diluted EPS−$0.14$3.17—
Operating cash flow$640.8M$1.27B−49.6%
Capital expenditure$40.40M$46.20M−12.6%
Free cash flow$600.4M$1.23B−51.0%

Operating KPIs for the quarter

Biogen operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Product revenue, net revenue$2.1Bup 13.1%
MS Product Revenues$919.3Mdown 13.4%
Rare Disease Product Revenue$676.3Mup 26.8%
Revenue from anti-CD20 therapeutic programs revenue$497.3Mup 0.7%
SPINRAZA revenue$460.6Mup 23.2%
TYSABRI revenue$437.1Mup 1.2%
Royalty Attributed To OCREVUS revenue$369.9Mdown 4.3%
Fumarate revenue$274.0Mdown 28.4%
Specialized Immunology revenue$242.8M—
Interferon revenue$208.2Mdown 15.7%
VUMERITY revenue$192.0Mdown 10.5%
SYFOVRE revenue$191.3M—
SKYCLARYS revenue$178.2Mup 34.1%
Biosimilars revenue$165.9Mdown 15.7%
AVONEX revenue$156.6Mdown 16.9%
Contract manufacturing, royalty and other revenue$149.7Mdown 1.0%
Contract manufacturing revenue$135.9Mdown 4.0%
BENEPALI revenue$117.3Mdown 3.8%
ZURZUVAE revenue$84.4Mup 52.6%
TECFIDERA revenue$82.0Mdown 51.2%

Earlier quarters

Biogen results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$2.80B+10.6%−$0.14
Q2 FY202630 Jun 2026$2.74B+3.4%$0.66
Q1 FY202631 Mar 2026$2.48B+1.9%$2.15
Q4 FY202531 Dec 2025$2.28B−7.1%−$0.33
Q3 FY202530 Sep 2025$2.53B+2.8%$3.17
Q2 FY202530 Jun 2025$2.65B+7.3%$4.33
Q1 FY202531 Mar 2025$2.43B+6.1%$1.64
Q4 FY202431 Dec 2024$2.45B+2.9%$1.83

More on Biogen: financial statements · revenue · earnings per share

BIIB's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.